BRPI0409292A - processo para a preparação de sal de cálcio amorfo de atorvastatina - Google Patents

processo para a preparação de sal de cálcio amorfo de atorvastatina

Info

Publication number
BRPI0409292A
BRPI0409292A BRPI0409292-9A BRPI0409292A BRPI0409292A BR PI0409292 A BRPI0409292 A BR PI0409292A BR PI0409292 A BRPI0409292 A BR PI0409292A BR PI0409292 A BRPI0409292 A BR PI0409292A
Authority
BR
Brazil
Prior art keywords
calcium
preparation
calcium salt
atorvastatin
atorvastatin calcium
Prior art date
Application number
BRPI0409292-9A
Other languages
English (en)
Inventor
Ljubomir Antoncic
Gorazd Sorsak
Anton Copar
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SI200300100A external-priority patent/SI21461A/sl
Priority claimed from SI200300138A external-priority patent/SI21505A/sl
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of BRPI0409292A publication Critical patent/BRPI0409292A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"PROCESSO PARA A PREPARAçãO DE SAL DE CáLCIO AMORFO DE ATORVASTATINA". A presente invenção refere-se ao processo de preparação de atorvastatina cálcica amorfa sem isolamento intermediário de atorvastatina cálcica cristalina ou mistura indefinida de atorvastatina cálcica amorfa e cristalina, respectivamente. A formação de sal de atorvastatina de cálcio é realizada em uma mistura de solvente orgânico clorado ou solvente de hidrocarboneto cíclico, respectivamente, o solvente orgânico não-hidroxílico, e água, a fonte de íons de cálcio é o acetato de cálcio ou o cloreto de cálcio, respectivamente.
BRPI0409292-9A 2003-04-11 2004-04-09 processo para a preparação de sal de cálcio amorfo de atorvastatina BRPI0409292A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI200300100A SI21461A (sl) 2003-04-11 2003-04-11 Priprava amorfne kalcijeve soli atorvastatina
SI200300138A SI21505A (sl) 2003-06-06 2003-06-06 Priprava amorfne kalcijeve soli atorvastatina
PCT/SI2004/000019 WO2004089895A1 (en) 2003-04-11 2004-04-09 Process for the preparation of amorphous calcium salt of atorvastatin

Publications (1)

Publication Number Publication Date
BRPI0409292A true BRPI0409292A (pt) 2006-04-11

Family

ID=33161664

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409292-9A BRPI0409292A (pt) 2003-04-11 2004-04-09 processo para a preparação de sal de cálcio amorfo de atorvastatina

Country Status (7)

Country Link
US (2) US8367848B2 (pt)
EP (1) EP1615884B1 (pt)
AU (1) AU2004228607B2 (pt)
BR (1) BRPI0409292A (pt)
CA (1) CA2520740C (pt)
EA (1) EA013500B1 (pt)
WO (1) WO2004089895A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE409476T1 (de) * 2002-06-13 2008-10-15 Novartis Pharma Gmbh Calciumsalze von statinen aus indol
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
CN101768102B (zh) * 2009-01-05 2013-08-21 浙江华海药业股份有限公司 一种阿托伐他汀钙中间体1h-吡咯衍生物的制备方法
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IN191236B (pt) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
US7563911B2 (en) * 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
ITMI20020907A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2006037125A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities

Also Published As

Publication number Publication date
WO2004089895A1 (en) 2004-10-21
US8697741B2 (en) 2014-04-15
EP1615884B1 (en) 2016-06-29
EA013500B1 (ru) 2010-06-30
EP1615884A1 (en) 2006-01-18
EA200501553A1 (ru) 2006-06-30
AU2004228607B2 (en) 2011-01-27
US20060287538A1 (en) 2006-12-21
CA2520740C (en) 2012-06-05
CA2520740A1 (en) 2004-10-21
AU2004228607A1 (en) 2004-10-21
US20090182030A1 (en) 2009-07-16
US8367848B2 (en) 2013-02-05

Similar Documents

Publication Publication Date Title
BR0213877A (pt) Compostos orgânicos
EA200901629A1 (ru) Способы и системы опреснения, включающие осаждение карбонатных соединений
BRPI0409292A (pt) processo para a preparação de sal de cálcio amorfo de atorvastatina
BRPI0407283A (pt) Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
BR0114729A (pt) Métodos para produzir cristais de nateglinida, e cristais do tipo h, cristais de nateglinida, e, cristais do tipo h de nateglinida
BR0213760A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
ATE501153T1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
BRPI0409471A (pt) processo para a preparação de 2-cianopirrolidinas n-substituìdas
BRPI0411738A (pt) compostos orgánicos
ATE442372T1 (de) Verfahren zur herstellung von cefoxitin
DE602007002794D1 (de) Behandlung von wässrigen flüssigkeiten und herstellung von anthranilsäure
Brittain Profiles of drug substances, excipients and related methodology
ATE253538T1 (de) Düngemittel-granulations-zusätze enthaltend magnesium- und kalzium- karbonat und sulfat
ATE355255T1 (de) Auflösungshemmende mittel zur herstellung von gereinigten solen
TW200833708A (en) Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture
DE69917282D1 (de) Verfahren zur herstellung von zofenopril-calciumsalz
BRPI0513272A (pt) compostos orgánicos
PL359495A1 (en) Method for producing peptide salts, their use, and pharmaceutical preparations containing these peptide salts
BR0109343A (pt) Processo para produzir camptotecina
NO20081151L (no) Derivater av 5-pyridinyl-1-azabicklo[3.2.1]oktan, fremgangsmate derav og anvendelse av de samme i terapi
RU2007123796A (ru) Способ получения водоустойчивой аммиачной селитры
CN105621557A (zh) 一种新型污水处理剂
RU2002134667A (ru) Способ получения водоустойчивой аммиачной селитры
UA84298C2 (ru) Способ получения кристаллического магний хлорида
WO2006098805A3 (en) Direct sequestration of chloride ions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 207/34; A61P 3/00

Ipc: C07D 207/34 (2011.01), A61P 3/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements